(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
EDX Medical Group PLC - Cambridge, England-based company that develops digital diagnostic products and services to treat cancer, heart disease, and infectious diseases - Announces a "strategic expansion" of its cancer testing capability. EDX Medical is to launch comprehensive hereditary germline cancer testing products and services "designed to accurately predict if family members of cancer patients are at increased risk from the disease." Adds that the first test to be made available to health professionals in the UK is a pan-cancer test which achieves 99% sensitivity and identifies mutations in 70 genes known to be associated with cancers which have a strong inherited, genetic component including prostate, breast, colorectal, pancreatic and ovarian cancers in a single test. Read More
(Alliance News) - EDX Medical Group PLC on Wednesday said its shares are now eligible to begin trading on the Apex segment of the Aquis Stock Exchange in London. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - EDX Medical Group PLC on Monday said it is performing "very strongly" and that it is now implementing its distribution of the Guardant360 CDx and Guardant Reveal tests to the UK private healthcare sector. Read More
(Alliance News) - EDX Medical Group PLC on Monday posted a "positive" outlook for its financial year, despite reporting a widened interim loss. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - EDX Medical Group PLC on Thursday said that it has entered a strategic agreement with Guardant Health Inc to distribute its blood-based liquid biopsy tests in the UK and the Nordics. Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
(Alliance News) - EDX Medical Group PLC on Friday said it has acquired Torax Biosciences Ltd, by issuing 1.7 million shares in the company at a deemed price of 6 pence per share. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
EDX Medical Group PLC - London-based developer of diagnostics products to help predict disease risk - Announces European cancer biomarker programme collaboration with Tianjin Bioscience Diagnostics Technology Co Ltd. The programme aims to improve access to reliable and cost-effective tests for cancers in the UK and Europe. EDX Medical will "conduct validation studies and submit data on individual tests to UK and EU Authorities for regulatory approval," it says. Tianjin Bioscience installed two automated digital chemiluminescence immunoassay instruments at EDX's laboratory in Cambridge. The instruments have a capacity to process up to 250,000 tests per year. Read More
EDX Medical Group PLC - London-based developer of diagnostics products to help predict disease risk - Started trading on AQSE last week following GBP12 million reverse takeover by special purpose acquisition company TECC Capital PLC. Raised GBP1.2 million via placing 20.0 million shares at 6 pence per share. Chair of newly restructured company is Jason Holt, and chief executive officer is Michael Hudson. Chief scientific officer is Christopher Evans. TECC's former chair Sandy Barblett, and former CEO John Taylor step down from the board. Read More